Inogen, Inc. INGN R2K
Healthcare · Medical Devices · United States
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.
READ MORE ›$6.49
+1.01% 1Y
Market & Price
Market Cap
$175.71M
Current Price
$6.49
High / Low (52W)
$8.95 / $5.59
Beta
1.65
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$6.68
Price to Book
0.97
P/S
0.50
EV/EBITDA
-9.36
Dividend Yield
-
Profitability & Returns
ROCE
-12.85%
ROE
-13.07%
ROA
-6.14%
Profit Margin
-7.08%
Op Margin
-9.89%
EPS (Latest Qtr)
$-0.30
EPS (TTM)
$-0.91
Balance Sheet & Liquidity
Debt/Equity
0.09
Quick Ratio
2.47
Current Ratio
3.10
Debt
$16.93M
Total Assets
$298.62M
Current Assets
$198.30M
Working Capital
$134.76M
Ownership
Promoter Holding
11.90%
Chg in Prom Hold
-
FII / Inst Holding
77.77%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$82.48M
Total Revenue (TTM)
$351.50M
EBITDA
$-8.81M
Free Cash Flow
$-2.41M
Operating Cash Flow
$-1.11M
Shares Outstanding
27.07M
Gross Margin
44.31%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-2.59%
Profit 5Y
24.28%
Revenue (YoY)
3.40%
Earnings (YoY)
-
PROS
- Profit CAGR of 24.3% over 5 years.
CONS
- Revenue declined at -2.6% CAGR over 5 years.
- Trading 27.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INGN Inogen, Inc. R2K | 6.49 | - | $175.71M | - | -12.85% | -13.07% | -2.59% | 24.28% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 58.04M | 63.14M | - | 73.58M | 91.99M | 89.71M | - | 84.82M | 95.86M | 86.39M | - | 83.14M | 65.61M | 66.81M | - | 77.08M | 90.30M | 80.97M | 67.40M | 89.29M | 90.67M | 55.89M | 68.34M | 67.97M | 63.09M | 74.42M | - | - | 82.28M | 92.28M | 92.39M | 81.72M | 85.11M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.91M | 50.94M | 51.07M | 46.48M | 47.25M |
| Gross Profit | 19.38M | 20.04M | 21.28M | 26.21M | 25.13M | 24.69M | 25.74M | 31.57M | 33.17M | 30.76M | 37.73M | 48.47M | 48.81M | 43.57M | 44.41M | 50.22M | 43.31M | 33.92M | 38.37M | 32.75M | 33.01M | 34.06M | 39.87M | 50.34M | 47.69M | 35.01M | 46.26M | 42.80M | 30.73M | 34.04M | 33.76M | 34.37M | 42.74M | - | - | 36.37M | 41.34M | 41.32M | 35.24M | 37.86M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.03M | 47.47M | 48.43M | 44.54M | 47.20M |
| Operating Income | 3.71M | - | 3.28M | 8.02M | 5.40M | - | 5.57M | 8.50M | 8.33M | - | 8.70M | 14.02M | 10.40M | - | 4.86M | 12.14M | 8.11M | - | -2.18M | -2.35M | -1.97M | - | -2.13M | 11.67M | 6.37M | -13.59M | -2.88M | -10.29M | -21.91M | -11.77M | -46.72M | -16.27M | -7.06M | - | - | -7.66M | -6.13M | -7.12M | -9.31M | -9.34M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.47M | -913.00K | -1.90M | -4.27M | -4.43M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.27M | -4.30M | -5.44M | -7.36M | -8.50M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -97.00K | -153.00K | -146.00K | -236.00K | -174.00K |
| Net Income | 2.70M | 3.86M | 2.52M | 7.49M | 5.25M | 5.26M | 5.93M | 8.34M | 7.34M | -606.00K | 10.76M | 14.61M | 16.43M | 10.04M | 5.30M | 10.16M | 6.86M | -1.38M | -1.59M | 2.58M | -1.70M | -5.12M | -732.00K | 5.10M | 12.17M | -14.21M | -3.44M | -9.51M | -20.35M | -9.83M | -45.72M | -14.58M | -5.59M | - | - | -6.17M | -4.15M | -5.29M | -7.13M | -8.32M |
| Diluted EPS | 0.13 | 0.19 | 0.12 | 0.36 | 0.25 | 0.25 | 0.27 | 0.38 | 0.33 | -0.03 | 0.48 | 0.65 | 0.73 | 0.44 | 0.24 | 0.45 | 0.31 | -0.06 | -0.07 | 0.12 | -0.08 | -0.23 | -0.03 | 0.22 | 0.53 | -0.62 | -0.15 | -0.42 | -0.88 | -0.42 | -1.97 | -0.62 | -0.24 | - | - | -0.25 | -0.15 | -0.20 | -0.26 | -0.30 |
| R&D Expense | 1.12M | - | 1.17M | 1.38M | 1.35M | - | 1.31M | 1.26M | 1.38M | - | 1.42M | 1.77M | 2.10M | - | 1.67M | 1.47M | 2.64M | - | 3.60M | 3.29M | 3.51M | - | 4.01M | 4.12M | 3.75M | 5.36M | 6.06M | 4.58M | 5.34M | 4.29M | 4.49M | 6.58M | 5.62M | 3.52M | - | 4.03M | 5.21M | 4.84M | - | 5.10M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 168.17M | 225.49M | 336.01M | 340.55M | 280.19M | - | 377.24M | 315.66M | 335.70M | 348.67M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 223.71M | 188.96M | 180.96M | 194.40M |
| Gross Profit | 23.95M | 38.99M | 55.52M | 76.26M | 97.31M | 121.24M | 178.58M | 171.86M | 138.18M | - | 153.53M | 126.70M | 154.74M | 154.26M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 186.62M | 203.19M | 197.26M | 184.47M |
| Operating Income | 829.00K | 4.46M | 10.51M | 15.05M | 22.86M | 27.59M | 37.89M | 19.79M | -12.03M | - | -33.08M | -76.49M | -42.52M | -30.21M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -9.57M | -58.34M | -21.51M | -9.55M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -83.27M | -102.34M | -36.48M | -23.38M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 504.00K | 105.00K | -588.00K | -632.00K |
| Net Income | 564.00K | 25.43M | 6.83M | 11.59M | 20.52M | 21.00M | 51.84M | 20.95M | -5.83M | - | -83.77M | -102.45M | -35.89M | -22.75M |
| Diluted EPS | -19.97 | 0.68 | 0.30 | 0.56 | 0.97 | 0.96 | 2.30 | 0.94 | -0.27 | - | -3.67 | -4.42 | -1.52 | -0.86 |
| R&D Expense | 2.26M | 2.40M | 2.98M | 4.18M | 5.11M | 5.31M | 7.03M | 9.40M | 14.08M | 16.58M | 21.94M | 20.84M | 21.61M | 19.40M |
Compounded Sales Growth
| 5 Years: | -2.59% |
| 1 Year: | 3.40% |
Compounded Profit Growth
| 5 Years: | 24.28% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +1.01% |
| 6 Months: | -8.46% |
| 3 Months: | +6.39% |
| 1 Month: | -7.29% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 82.40M | 140.09M | 161.31M | 180.78M | 197.52M | 211.31M | 214.05M | 275.07M | 375.90M | 447.34M | 461.85M | - | 405.04M | 326.19M | 296.19M | 298.62M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 304.64M | 207.07M | 185.45M | 198.30M |
| Cash & Equivalents | 3.91M | 15.11M | 13.52M | 56.84M | 66.11M | - | - | - | 92.85M | 142.95M | 196.63M | 198.04M | 211.96M | - | 187.01M | 125.49M | 113.80M | 103.73M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.09M | 21.84M | 24.81M | 25.97M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 62.73M | 42.24M | 29.56M | 38.86M |
| Total Liabilities | - | - | 26.10M | 21.93M | 27.30M | - | - | - | 31.96M | 48.03M | 65.47M | 102.72M | 112.23M | - | 107.64M | 121.38M | 122.33M | 106.39M |
| Current Liabilities | - | - | 18.83M | 18.73M | 22.01M | - | - | - | 22.84M | 33.89M | 46.59M | 50.18M | 56.71M | - | 65.35M | 72.50M | 76.69M | 63.53M |
| Long Term Debt | - | - | 5.39M | 315.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.28M | 21.92M | 19.41M | 17.48M |
| Total Equity | -75.57M | -80.77M | -62.37M | 118.15M | 134.02M | 150.57M | 162.24M | 172.60M | 182.09M | 227.04M | 310.42M | 344.62M | 349.62M | - | 297.41M | 204.81M | 173.86M | 192.23M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.94M | 22.94M | 23.90M | 27.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | 31.03M | 60.49M | 59.98M | 40.59M | 37.01M | - | -37.53M | -3.23M | 5.91M | -11.22M |
| Investing Cash Flow | - | - | - | - | -11.93M | -24.43M | -24.96M | -44.06M | -25.64M | - | -10.88M | -59.31M | -13.97M | -26.21M |
| Financing Cash Flow | - | - | - | - | 7.71M | 14.00M | 18.30M | 4.93M | 2.07M | - | 380.00K | 960.00K | 265.00K | 24.18M |
| Capital Expenditure | -2.02M | -3.03M | -1.55M | -2.21M | -1.72M | -2.91M | -8.04M | -3.14M | -4.38M | - | -21.22M | -27.01M | -17.09M | -10.38M |
| Free Cash Flow | - | - | - | - | 29.32M | 57.58M | 51.93M | 37.45M | 32.63M | - | -58.75M | -30.25M | -11.18M | -21.60M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -48.03M | -61.59M | -7.80M | -13.24M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 57.9% | 53.8% | 53.1% | 50.5% | 49.3% | - | 40.7% | 40.1% | 46.1% | 44.2% |
| Operating Margin % | - | - | - | - | 13.6% | 12.2% | 11.3% | 5.8% | -4.3% | - | -8.8% | -24.2% | -12.7% | -8.7% |
| Net Margin % | - | - | - | - | 12.2% | 9.3% | 15.4% | 6.2% | -2.1% | - | -22.2% | -32.5% | -10.7% | -6.5% |
| ROE % | -0.7% | -40.8% | 5.8% | 8.6% | 11.3% | 9.3% | 16.7% | 6.1% | -1.7% | - | -28.2% | -50.0% | -20.6% | -11.8% |
| ROCE % | - | 7.0% | 8.7% | 10.8% | 12.0% | 11.4% | 11.5% | 5.0% | -3.0% | - | -9.7% | -30.2% | -19.4% | -12.8% |
Shareholding Pattern
Insiders
11.90%
Institutions
77.77%
Public Float
88.27%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 6.08% | 1.65M | $10.69M |
| 2 | Armistice Capital, LLC | 4.43% | 1.20M | $7.79M |
| 3 | Acadian Asset Management. LLC | 4.00% | 1.08M | $7.03M |
| 4 | Vanguard Capital Management LLC | 3.83% | 1.04M | $6.73M |
| 5 | Ameriprise Financial, Inc. | 3.17% | 859.54K | $5.58M |
| 6 | DAFNA Capital Management, LLC | 3.12% | 845.18K | $5.49M |
| 7 | Point72 Asset Management, L.P. | 2.37% | 642.37K | $4.17M |
| 8 | Geode Capital Management, LLC | 2.27% | 613.53K | $3.98M |
| 9 | Arrowstreet Capital, Limited Partnership | 2.16% | 586.16K | $3.80M |
| 10 | Goldman Sachs Group Inc | 2.14% | 580.10K | $3.76M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INGN
No recent headlines available.